Drug analysis

A
B-C
D-F
Drug Analysis
G-L
M-O
P-R
S-T
U-Z

Sort by Random

Display 45 Products per page

Tecentriq
Read More
Tecentriq (atezolizumab; Roche/Chugai) is an antibody designed to target programmed death-ligand 1 (PD-L1) on tumor cells, allowing the body’s immune system to recognize and properly respond to the tumor.
February 26, 2020
Find out more
Herceptin
Read More
Herceptin is a humanized MAb targeting the HER2 receptor, a member of the human epidermal

growth factor receptor family.
March 22, 2016
Find out more
Activase
Read More
Activase (alteplase; Roche/Boehringer Ingelheim/Kyowa Hakko Kirin) is a recombinant tissue plasminogen activator, and is a manufactured version of the tissue plasminogen activating proteins found naturally in endothelial cells.
July 2, 2018
Find out more
Talzenna
Read More
Talzenna (talazoparib; Pfizer) is a small-molecule inhibitor of poly (ADP-ribose) polymerase (PARP). PARP inhibitors block the activity of PARP, an enzyme that plays an essential role in DNA repair mechanisms and homologous recombination events, by directly blocking enzymatic activity, or by causing PARP to accumulate on DNA (PARP trapping), which results in DNA replication inhibition and cell death.
February 26, 2020
Find out more
Cayston
Read More
Cayston is an inhalable formulation of the monobactam antibacterial aztreonam and was developed by Gilead.
September 3, 2018
Find out more
Adynovate
Read More
Adynovate is a long-acting PEGylated recombinant factor VIII (rfVIII) therapy developed by Baxalta and Nektar Therapeutics as a follow-on to Advate (rfVIII; Shire).
May 4, 2018
Find out more
Pradaxa
Read More
Pradaxa (dabigatran; Boehringer Ingelheim) is an orally available direct thrombin inhibitor (factor IIa inhibitor) indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients who previously received treatment with a parenteral anticoagulant for five to 10 days.
March 15, 2018
Find out more
Trumenba
Read More
Trumenba (Pfizer) is a bivalent recombinant meningococcal serogroup B vaccine indicated for immunization to prevent invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B in individuals aged 10−25 years in the US. Trumenba is a sterile suspension composed of two recombinant lapidated factor H binding protein variants. Factor H binding protein is found on the surface of meningococci and enhances the bacterium’s ability to avoid host defense.
September 3, 2019
Find out more
bardoxolone methyl
Read More
Bardoxolone methyl (AbbVie/Kyowa Hakko Kirin), under development by the research-stage company Reata Pharmaceuticals, is a Phase III candidate in clinical trials for the treatment of pulmonary arterial hypertension.
October 29, 2018
Find out more
Lusefi
Read More
Lusefi (luseogliflozin; Taisho) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class.
November 7, 2017
Find out more
Aricept
Read More
Aricept (donepezil; Eisai/Pfizer) has been the gold standard in the treatment of all stages of
Alzheimer’s disease for more than a decade.
September 2, 2016
Find out more
ProstAtak
Read More
ProstAtak (AdV-tk + valacyclovir) is a viral cancer vaccine being developed by Advantagene for the treatment of prostate cancer. It works by gene-mediated cytotoxic immunotherapy, an approach that generates a tumor-specific vaccine.
September 24, 2015
Find out more
Seebri Neohaler
Read More
Novartis, under license from Vectura and Sosei, developed Seebri Neohaler, a once-daily inhaled formulation of glycopyrrolate.
July 31, 2018
Find out more
Erdafitinib
Read More
Erdafitinib (Johnson & Johnson/Otsuka) is a small molecule inhibitor that targets fibroblast growth factor receptors (FGFRs), which play a role in the angiogenesis pathway, facilitating tumor growth and metastasis.
July 4, 2017
Find out more
Invega Sustenna/Invega Trinza
Read More
Invega Sustenna and Invega Trinza (paliperidone palmitate; Johnson & Johnson) are long-acting injectable formulations developed by Johnson & Johnson, using with Alkermes’s technology.
March 19, 2018
Find out more
Triumeq
Read More
Triumeq ([dolutegravir + abacavir + lamivudine]; ViiV Healthcare) is a single-tablet regimen (STR) for the treatment of HIV-1 infection. It is a co-formulation of the marketed HIV drugs Tivicay (dolutegravir; ViiV Healthcare) and Epzicom ([abacavir + lamivudine]; ViiV Healthcare), which is known as Kivexa outside the US. Tivicay is an integrase inhibitor that blocks the insertion of the viral genome into the host genome, and Epzicom is a fixed-dose combination nucleoside reverse transcriptase inhibitor that prevents viral RNA replication.
June 28, 2019
Find out more
Victoza
Read More
Victoza (liraglutide; Novo Nordisk) is a member of the glucagon-like peptide-1 (GLP-1) agonist class. GLP-1 agonists are incretin mimetics, mimicking the endogenous gut hormone GLP-1, which stimulates insulin-secreting beta cells in the pancreas.
July 7, 2017
Find out more
Macugen
Read More
Macugen (pegaptanib; Valeant/Pfizer) is a PEGylated oligonucleotide aptamer which binds selectively

to vascular endothelial growth factor (VEGF)-165, an isoform of VEGF found to induce angiogenesis

and increase vascular permeability (Natarajan, 2013).
April 7, 2016
Find out more
Ensartinib
Read More
Ensartinib is a second-generation ALK inhibitor developed by Xcovery. In approximately 3–5% of all NSCLC patients, abnormal ALK configuration leads to the production of proteins that promote and maintain the malignant behavior of cancer cells (Soda et al., 2008; Solomon et al., 2013).
August 30, 2018
Find out more
Stelara
Read More
Stelara (ustekinumab; Johnson & Johnson/Mitsubishi Tanabe) is a high-affinity, fully human monoclonal antibody that targets the p40 subunit of cytokines interleukin (IL)-12 and IL-23 proteins that occur in the immune system.
August 2, 2018
Find out more
Tymlos transdermal patch
Read More
Tymlos (abaloparatide; Radius Health) is a synthetic peptide analog of human parathyroid hormone-related protein (PTHrP), which binds to the same receptor as parathyroid hormone (PTH).
October 8, 2019
Find out more
Opdivo
Read More
Opdivo is a fully human immunoglobulin G4 PD-1 immune checkpoint inhibitor that binds to the checkpoint receptor PD-1 expressed on activated T cells.
September 9, 2019
Find out more
Votrient
Read More
Votrient (pazopanib; Novartis) is an oral angiogenesis inhibitor targeting the vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and c-KIT. Preclinical studies have shown the role of PDGF in modulating angiogenesis
March 6, 2019
Find out more
Nucala
Read More
Nucala (mepolizumab; GlaxoSmithKline) is a humanized monoclonal immunoglobulin G1 antibody that binds to interleukin (IL)-5, which plays a significant role in the activation, proliferation, and differentiation of eosinophils.
July 31, 2018
Find out more
Copiktra
Read More
Copiktra (duvelisib; Verastem/Yakult Honsha) is a highly selective small molecule inhibitor of the p110-delta and p110-gamma isoforms of the phosphoinositide 3-kinase (PI3K) enzyme.
January 31, 2019
Find out more
Delafloxacin
Read More
Delafloxacin is a novel broad-spectrum fluoroquinolone that prevents bacterial DNA synthesis through its equal inhibitory effect against the enzymes topoisomerase II (DNA gyrase) and IV.
September 10, 2014
Find out more
Selinexor
Read More
Selinexor (Karyopharm/NPM Pharma) selectively inhibits the transport protein exportin-1 (XPO1), also called chromosome region maintenance-1.
October 9, 2018
Find out more
Nucynta
Read More
Nucynta (tapentadol; Collegium Pharmaceutical) first gained US Food and Drug Administration (FDA) approval in November 2008 as an immediate-release formulation, for the relief of acute pain, and was the first novel opioid to be launched for pain in more than 25 years.
May 31, 2018
Find out more
Seroquel/Seroquel XR
Read More
The Seroquel franchise contains quetiapine, which acts as an antagonist at multiple neurotransmitter receptors in the brain, such as serotonin 5-HT1A and 5-HT2, dopamine D1 and D2, histamine H1, and adrenergic alpha 1 and alpha 2 receptors.
March 29, 2019
Find out more
Zontivity
Read More
Zontivity (vorapaxar; Merck & Co) gained US and EU approval for the reduction of thromboembolic

events in secondary-prevention patients with a history of myocardial infarction (MI).
April 14, 2016
Find out more
CB-839
Read More
Cancer cells are known to rely on glycolysis as an energy source. CB-839 (Calithera Biosciences) inhibits the glutaminase enzyme, reducing the ability of cancer cells to utilize glutamine in this biochemical pathway, thereby reducing cell proliferation and tumor growth.
March 6, 2019
Find out more
Truvada
Read More
Truvada ([emtricitabine + tenofovir disoproxil fumarate (TDF)]; Gilead/Japan Tobacco) is a once-daily, fixed-dose combination of two of Gilead’s marketed nucleoside reverse transcriptase inhibitors (NRTIs):
June 28, 2019
Find out more
Nimenrix
Read More
Nimenrix (quadrivalent polysaccharide tetanus toxoid conjugate vaccine; Pfizer) is a conjugated polysaccharide vaccine indicated for active immunization to prevent invasive meningococcal disease (IMD) caused by Neisseria meningitidis (N. meningitidis) serogroups A, C, Y, and W-135 in individuals from the age of six weeks. It induces the production of bactericidal antibodies against capsular polysaccharides of N. meningitidis group A, C, W-135, and Y.
September 3, 2019
Find out more
Gilotrif
Read More
Gilotrif is an orally administered TKI that irreversibly binds to EGFR/human epidermal growth factor receptor 1 (HER1), HER2, and HER4.
August 30, 2018
Find out more
Ongentys
Read More
Ongentys (Neurocrine/Bial/Ono Pharmaceutical) is a once-daily formulation of the catechol-O-methyltransferase (COMT) inhibitor opicapone, approved as an add-on therapy to levodopa for the treatment of Parkinson’s disease patients with end-of-dose motor fluctuations.
June 21, 2018
Find out more
Invokana
Read More
Invokana (canagliflozin; Johnson & Johnson/Mitsubishi Tanabe/Daiichi Sankyo) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class.
February 27, 2019
Find out more
V114
Read More
Merck & Co’s V114 is a 15-valent pneumococcal capsular polysaccharide conjugate vaccine, which is currently in Phase III development in the US and EU.
December 21, 2018
Find out more
Injectafer
Read More
Injectafer (ferric carboxymaltose; Vifor/Luitpold Pharmaceuticals/Zeria) is an iron maintenance treatment used to help elevate hemoglobin levels in patients with anemia in chronic kidney disease (CKD). It is administered intravenously and is dissociated into iron and sucrose once in circulation.
January 11, 2018
Find out more
Viibryd
Read More
Viibryd (vilazodone; Allergan) belongs to a new class of antidepressants, combining selective serotonin reuptake inhibitor activity with partial 5-HT1A receptor agonism, in order to produce its therapeutic effect.
March 29, 2019
Find out more
DCVAC/PCa
Read More
DCVAC/PCa is a cell-based cancer vaccine composed of autologous dendritic cells which are activated to recognize a prostate cancer cell line. When infused into patients, the primed dendritic cells cause activation of T cells…
January 18, 2018
Find out more
Gilenya
Read More
Gilenya is a synthetic derivative of ISP-1 (myriocin), a fungal metabolite of the Chinese herb isaria sinclarii which acts as a potent agonist at four of the S1P receptors (S1P1, S1P3, S1P4, and S1P5).
November 24, 2017
Find out more
Effient
Read More
An oral antiplatelet agent, Effient is a pro-drug which is converted to its active metabolite after
metabolism by cytochrome P450 enzymes.
April 14, 2016
Find out more
Sutent
Read More
Sutent (sunitinib; Pfizer) is an orally available multi-targeted tyrosine kinase inhibitor which specifically inhibits vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), c-KIT, and FLT3.
March 6, 2019
Find out more
Vibativ
Read More
Vibativ is a lipoglycopeptide antibiotic that is a semisynthetic derivative of vancomycin. The drug exhibits a dual bactericidal mechanism of action.
September 10, 2014
Find out more
Rubraca
Read More
Rubraca (rucaparib) is a small molecule poly (ADP-ribose) polymerase (PARP) inhibitor developed by Clovis Oncology for the treatment of recurrent ovarian cancer patients with known BRCA mutations or other homologous recombination gene alterations.
January 18, 2018
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *